

# Integrated Hypothesis of Schizophrenia

Nuriel Mor

Walden University

## Different Hypotheses of Schizophrenia

### Dopamine Hypothesis of Schizophrenia

- Hyper Activity of D2 Receptors
- level of affinity of a drug to D2 and efficacy in reducing psychosis
- Amphetamine Induces Psychosis
- Genetic Studies (COMT, DRD4, and AKT1)
- PET Studies: D2 receptors blocked, psychosis was not reduced.
- D2 receptors are blocked within few minutes but it takes several weeks until some improvement is observed.

### Serotonin Involvement

- 5-HT-2A Receptors Agonists (LSD)
- Atypical Antipsychotics

### Glutamate Hypothesis of Schizophrenia

- NMDA Receptor Antagonists(PCP, Ketamine)
- Mice with decreased NMDA receptor activity showed symptoms of schizophrenia.
- Influence of D-serine NMDA receptor neuromodulator(agonist).

### Excessive Release of Glutamate

- Damage and deterioration of cortical neurons, enlarged ventricles and extensive atrophy are attributed to glutamate toxicity
- Drug that decrease the amount of glutamate in the synapses found to have an antipsychotic effect (LY2140023).

## Integrated Hypothesis of Schizophrenia


The purpose is to integrate all of this different hypotheses of schizophrenia under one connected biochemical mechanism. To find the mechanism that is responsible for all of these different findings.

Hypo function of NMDAR is a central component of this hypotheses.

- NMDAR hypo function mediated by hypo activity of GABAergic neurons leads to hyper activity of dopaminergic neurons in the VTA and increased release of dopamine in the limbic system.
- NMDAR hypo function mediated by hypo activity of GABAergic neurons leads to hyper activity of glutamatergic neurons and the excessive release of glutamate
- Glutamate in excess binds to non NMDA receptors of glutamate, such as AMPA and Kainate receptors which lead to an increased activity of dopaminergic neurons in the VTA and increased release of dopamine in the limbic system.

How can this Hypothesis be Supported or Refuted?

Evidence that AMPA agonists increase the levels of dopamine in the brain. Not investigated in the context of schizophrenia or with animal models of schizophrenia.



#### References

- Arguello, A., Gogos, A. (2008). A signaling pathway AKTing up in schizophrenia The Journal of Clinical Investigation 118 (6): 2018–2021.
- Carlson, N. R. (2013). Physiology of behavior. Pearson
- Dalack, G., Meador-Woodruff, H. (1998). Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. American journal of psychiatry 155 (11): 1490–1501
- Del Arco, A., & Mora, F. (2002). NMDA and AMPA/kainate glutamatergic agonists increase the extracellular concentrations of GABA in the prefrontal cortex of the freely moving rat: modulation by endogenous dopamine. Brain research bulletin, 57(5), 623-630.
- Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A. V. R. A. H. A. M., & Kelly, D. A. L. I. A. (1996). Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. The British Journal of Psychiatry, 169(5), 610-617.
- Hersen, M., & Beidel, D. C. (Eds.). (2012). Adult psychopathology and diagnosis (6th ed.). Hoboken, NJ: John Wiley & Sons.
- Jentsch, J. D., & Roth, R. H. (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 20(3), 201-225
- Julien, R. M., Advokat, C. D., & Comaty, J. E. (2014). Julien's primer of drug action: A comprehensive guide to the actions, uses, and side effects of psychoactive drugs (13th ed.). New York, NY: Worth.
- Lieberman, J. A.; Kane, J. M.; Alvir, J. (1987). Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91 (4): 415–433
- Mayer, M. L. (2005). Glutamate receptor ion channels. Current Opinion in Neurobiology 15 (3): 282–288
- Mohn, Amy; Gainetdinov Caron Koller (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (4): 427–436.
- Mothet, Jean-Pierre; Parent, Angèle T.; Wolosker, Herman; Brady, Roscoe O., Jr.; Linden, David J.; Ferris, Christopher D.; Rogawski, Michael A.; Snyder, Solomon H. (2000). d-Serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor, Proc. Natl. Acad. Sci. USA 97 (9): 4926–31,
- Olney, J. W., & Farber, N. B. (1995). Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry, 52(12), 998-007.
- Pierce RC, Kumaresan V. (2006). The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse? Neuroscience and Biobehavioral Reviews 30:215-38
- Preston, J. D., O'Neal, J. H., & Talaga, M. C. (2013). Handbook of clinical psychopharmacology for therapists (7th ed.). Oakland, CA: New Harbinger rugs (13th ed.). New York, NY: Worth.
- Shwarzman, O. (2007) White doctor black gods. Aryeh Nir publishers. Tel Aviv:Israel.
- Woolley, M. L., Pemberton, D. J., Bate, S., Corti, C., & Jones, D. N. C. (2008). The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology, 196(3), 431-440.